Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial-Reference-Cited by-同舟云学术

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

Published:2017-05 Issue:5 Volume:5 Page:390-400
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Chupp Geoffrey L,Bradford Eric S,Albers Frank C,Bratton Daniel J,Wang-Jairaj Jie,Nelsen Linda M,Trevor Jennifer L,Magnan Antoine,ten Brinke Anneke

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference26 articles.

2. Asthma: defining of the persistent adult phenotypes;Wenzel;Lancet,2006

3. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma;Chung;Eur Respir J,2014

4. Asthma exacerbations and lung function in patients with severe or difficult-to-treat asthma;Calhoun;J Allergy Clin Immunol,2015

5. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire;Jones;Am Rev Respir Dis,1992

Cited by 462 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The new biologic drugs: Which children with asthma should get what?;Pediatric Pulmonology;2024-09-13

2. New Therapies in Outpatient Pulmonary Medicine;Medical Clinics of North America;2024-09

3. Comparative safety of monoclonal antibodies in chronic inflammatory airway diseases (chronic sinusitis with nasal polyposis and asthma): A network meta-analysis;International Immunopharmacology;2024-09

4. Investigation of lactotransferrin messenger RNA expression levels as an anti–type 2 asthma biomarker;Journal of Allergy and Clinical Immunology;2024-09

5. From Pathogenesis to Treatment: Targeting Type-2 Inflammation in Eosinophilic Esophagitis;Biomolecules;2024-08-28